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In Vitro and In Vivo Preclinical Testing of Pericyte-Engineered Grafts
for the Correction of Congenital Heart Defects
Valeria Vincenza Alvino, MSc; Michael Kilcooley, MSc; Anita C. Thomas, PhD; Michele Carrabba, PhD; Marco Fagnano, MSc;
William Cathery, MSc; Elisa Avolio, PhD; Dominga Iacobazzi, PhD; Mohamed Ghorbel, PhD; Massimo Caputo, MD; Paolo Madeddu, MD
Background-—We have previously reported the possibility of using pericytes from leftovers of palliative surgery of congenital heart
disease to engineer clinically certified prosthetic grafts.
Methods and Results-—Here, we assessed the feasibility of using prosthetic conduits engineered with neonatal swine pericytes to
reconstruct the pulmonary artery of 9-week-old piglets. Human and swine cardiac pericytes were similar regarding anatomical
localization in the heart and antigenic profile following isolation and culture expansion. Like human pericytes, the swine surrogates
form clones after single-cell sorting, secrete angiogenic factors, and extracellular matrix proteins and support endothelial cell
migration and network formation in vitro. Swine pericytes seeded or unseeded (control) CorMatrix conduits were cultured under static
conditions for 5 days, then they were shaped into conduits and incubated in a flow bioreactor for 1 or 2 weeks. Immunohistological
studies showed the viability and integration of pericytes in the outer layer of the conduit. Mechanical tests documented a reduction in
stiffness and an increase in strain at maximum load in seeded conduits in comparison with unseeded conduits. Control and pericyte-
engineered conduits were then used to replace the left pulmonary artery of piglets. After 4 months, anatomical and functional
integration of the grafts was confirmed using Doppler echography, cardiac magnetic resonance imaging, and histology.
Conclusions-—These findings demonstrate the feasibility of using neonatal cardiac pericytes for reconstruction of small-size
branch pulmonary arteries in a large animal model. ( J Am Heart Assoc. 2020;9:e014214. DOI: 10.1161/JAHA.119.014214.)
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C ongenital heart disease (CHD) is the most common typeof birth defect. Worldwide, 1.35 million babies are born
with CHD each year, of which ~5000 are in the United Kingdom
alone.1,2 One major problem in the correction of congenital
cardiac defects is that prosthetic grafts can only remodel
through repopulation by invading cells from neighbor tissues
and the circulation. This spontaneous reparative process is not
rapid enough to prevent a progressive mismatch between the
graft and recipient’s heart. In severe cases, like tetralogy of
Fallot, a palliative “shunt” operation becomes necessary to
allow to direct blood flow to the lungs and relieve cyanosis
before the definitive correction. This temporal window may
provide a scope for expanding cardiac cells from surgery
leftovers to generate living prostheses. Prostheses endowed
with immediate growing capacity ahead of implantation could
be better suited tomatch the rapid growth of a baby’s heart than
the currently available acellular grafts.
Our previous study has shown that leftovers of palliative
surgery can be used to isolate and expand a population of
cardiac stromal cells with the characteristics of pericytes.3
We have proposed that cardiac pericytes (CPs) could be
used to engineer prosthetic grafts for the definitive
correction of right ventricle outflow defects.3 Compared
with competitive solutions, such as vein-derived autologous
endothelial cells (ECs) or peripheral blood-derived endothe-
lial progenitor cells,4–6 CPs have the advantage of being
tissue specific and capable of differentiating into vascular
smooth muscle cells and producing extracellular matrix
(ECM) proteins.3 Moreover, CPs may favor graft endothe-
lialization through their powerful angiocrine secretome.3 In
an initial manufacturing attempt, we seeded human neona-
tal CPs onto CorMatrix, a decellularized porcine ECM
clinically approved for use in cardiac surgery.3 After 3-week
culture in a flow bioreactor, the conduit was colonized by
the proliferating seeded CPs.
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Tomake a step forward in the translational pathway, we have
now designed a new study aimed at testing the feasibility of
implanting CP-engineered conduits in piglets using the same
procedure utilized to reconstruct branch pulmonary arteries
(PAs) in CHD patients. Human CPs represent the final cellular
product. However, preclinical testing of human cells in piglets
would require early chronic immunosuppression, which could
result in confounding and ethically unacceptable adverse
effects.7–9 As a surrogate, we used allogeneic CPs isolated
from littermates of the recipient piglet after demonstration of
similarities with neonatal human CPs.
Methods
The article adheres to the American Heart Association
journals’ implementation of the Transparency and Openness
Promotion Guidelines. In accordance with this policy, authors
will make the data, methods used in the analysis, and
materials used to conduct the research available to any
researcher for purposes of reproducing the results or
replicating the procedure.
Ethics
Institutional review board approval for the study was
obtained, according to the guidelines noted in the Journal
Instructions to Authors. Animal experiments were per-
formed in accord with institutional guidelines and followed
the principles stated in the Guide for Care and Use of
Laboratory Animals published by the National Institutes of
Health in 1996 and in the Animals (Scientific Procedures)
Act published in 1986. The protocol was covered by the UK
Home Office ethical approval PPL 30/3019 and
PF6E6335D. The report of experimental data follows the
Animal Research: Reporting of In Vivo Experiments (ARRIVE)
guidelines.10
Collection of Cardiac Tissue for CP Isolation
Cardiac tissue and peripheral blood were collected from
4-week-old large white/Landrace piglets for isolation/expan-
sion and characterization of swine CPs (sCPs) and peripheral
blood mononuclear cells, respectively. Sample attribution to
experimental analyses is provided in Table S1.
In Situ Immunohistochemistry and
Immunocytochemistry Characterization of sCPs
Details of the methodology used for immunofluorescent
microscopy studies are reported in Data S1. The list and
source of antibodies are reported in Table S2.
Production of sCP Stocks
Isolation and expansion of sCPs were performed using an
adaptation of the good manufacturing practice–compliant
standard operating procedure previously used on human
neonatal hearts (details in Data S1).3 At passage 2, cells were
split for further expansion or generation of frozen stocks.
Assessment of sCP Characteristics
Cell were studied at passage 5/6, using from 3 to 7
biological replicates (run in triplicate), unless otherwise
specified. Antigenic profile: Immunofluorescence microscopy
(N=7) and flow cytometry analyses (N=3) were performed
using the procedures and antibodies described in Data S1
and Tables S2 and S3. Viability, growth curves, and doubling
time: Three fresh or frozen-thawed sCP lines were seeded
onto a 6-well plate at a density of 3000/cm.2 They were
detached at days 4, 5, 6, 7, and 8 of culture and counted
using trypan blue (Thermo Fisher Scientific, Loughborough,
UK). Clonogenic assay: The test was performed on 2 sCP
lines at passage 3, using a motorized device connected to
the flow cytometric sorter (Cyclone; Beckman Coulter, Brea,
CA). A comparative assay between fresh and frozen-thawed
sCPs was performed to assess whether both conditions
allow for the generation of clones. Expression of angiogenic
factors: Quantitative PCR was performed on cells (N=5
biological replicates) cultured under normoxia (21% oxygen)
using a Quant Studio 6 Flex Real-Time PCR system (Applied
Biosystems, Foster City, CA). mRNA expression level was
Clinical Perspective
What Is New?
• We have successfully isolated pericytes from the heart of
piglets and expanded them to engineer clinical-grade
extracellular matrix scaffolds.
• We have provided evidence of feasibility of using a pericyte
cellularized scaffold for reconstruction of the pulmonary
artery in a piglet model.
What Are the Clinical Implications?
• Currently, repeated interventions are required because of
the limited remodeling capacity of the acellular material
used for correction of cardiac defects.
• In severe cases, palliation becomes necessary before a
definitive surgery correction.
• Cardiac pericytes available from leftover tissue of palliative
repair could be used to engineer clinical-grade matrix
conduits ready for implantation at the occasion of definitive
correction of the pulmonary artery defect.
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determined using the 2-DCt method. Swine pulmonary artery
ECs (sPAECs) were used as control. Taqman probes used in
these studies are reported in Table S4. Secretion of
angiogenic factors: Dedicated antihuman ELISA kits (R&D
Systems, Minneapolis, MN, US) were used to measure
immunoreactive levels of VEGF-A (vascular endothelial
growth factor A), ANG1 (angiopoietin 1), ANG2 (angiopoietin
2), and FGF-2 (fibroblast growth factor 2) proteins in
Figure 1. Characterization of swine cardiac pericytes. (A and B) Perivascular localization of sCPs in situ. Immunofluorescence
images showing the localization of CD31–/CD34+/NG2+ CPs in swine hearts around capillaries (A) and arterioles (B). Inserts
showing CD34 labeled in green fluorescence, NG2 in red, and CD31 in white; nuclei are recognized by blue fluorescence of DAPI.
Arrows indicate CPs around capillaries and an arteriole. Images taken at 2009 magnification. C, Phase contrast microscopy image
of sCPs displaying spindle-shape features (magnification,9100). (D and E) Graphs showing the growth curve (D) and viability (E) of
3 sCP lines that were seeded at 3000 cells/cm2 at day 1 and detached and counted at days 4, 5, 6, 7, and 8 of culture.
F, Immunofluorescence microphotographs showing the expression of neural/glial antigen 2 (NG2) and platelet-derived growth
factor receptor beta (PDGFRB), vimentin, CD73, cardiac transcriptional factor GATA-binding protein 4 (GATA-4), and the stemness
markers, sex determining region Y-box 2 (SOX-2) and octamer-binding transcription factor 4 (OCT-4). Cells are negative for NANOG
and the endothelial cell markers, vascular endothelial-cadherin (VE-cadherin) and CD31. sCPs express alpha-smooth muscle actin
(a-SMA) and calponin (CALP) and are negative for transgelin (TAGLN), smoothelin (SMTN), and smooth muscle myosin heavy chain
(SMMHC). Expression of Ki67 is indicative of proliferating cells. DAPI (blue) identifies nuclei. Scale bars=100 lm. G, Values in bar
graph represent the meanSEM of 7 biological replicates from immunocytochemistry studies. Fluorescence was normalized by
nuclei count. (H and I) Flow cytometry analysis of 3 sCP lines at P5. H, Representative graphs for each surface marker; negative
control staining profiles are shown by the red histograms, whereas specific antibody staining profiles are shown by light blue
histograms. I, Bar graph shows the meanSEM values of 3 sCP lines. (J and K) Immunofluorescent images and flow cytometry
histograms are also shown for swine pulmonary artery endothelial cells (PAECs) (J) and peripheral blood mononuclear cells
(PBMNCs; K). APC indicates allophycocyanin; BF, bright field; CD, cluster of differentiation; DAPI, 40,6-diamidin-2-fenilindolo; FITC-A,
fluorescein-area; PE-A, phycoerythrin-area; PE-Cy7, phycoerythrin–cyanine 7; sCP, swine cardiac pericytes.
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conditioned media (CM) from sCPs, which were cultured
under normoxia (N=4 biological replicates). Endothelial
network formation: The capacity of cells to form networks
on Matrigel was assessed using sCPs or sPAECs alone or
both in coculture (N=4 biological replicates). In addition,
network formation capacity of sPAECs was assessed follow-
ing stimulation with sCP-CM or unconditioned media.
Chemotactic activity: We tested the capacity of the sCP-
CM (N=4 biological replicates) to induce the migration of
sPAECs in a transwell cell-culture system. Endothelial cell
basal medium-2 basal medium or endothelial cell basal
medium-2 supplemented with 100 ng/mL of swine recom-
binant VEGF-A were used as controls. In separate assays, an
antagonist of Tie2 kinase receptor was used to contrast the
effect of sCP-CM on migration. Endothelial proliferation: The
capacity of sCPs and sCP-CM (N=4 biological replicates) to
promote sPAEC proliferation was assessed by the Click-iT
EdU Cell Proliferation Kit for Imaging, Alexa Fluor 488 dye
(Thermo Fisher Scientific). sPAECs maintained in uncondi-
tioned medium were used as a control.
Static Culture of sCPs on CorMatrix
Pieces of CorMatrix ECM were primed with endothelial cell
growth medium-2 media for 48 hours and then seeded with
sCPs (passage 5; 20 000/cm2) and cultured for 5 days in a
48-well plate. The CM was then collected and the CorMatrix
samples were cut in 3 pieces: One was fixed and paraffin-
embedded for histological studies; the other 2 were frozen for
optimal cutting temperature embedding and for RNA and
protein analyses. Eight biological replicates were examined,
unless differently specified.
Dynamic Culture of sCPs on CorMatrix
After completion of the 5-day static culture, sCP-seeded
CorMatrix was matured in a 3-dimensional CulturePro Biore-
actor (TA Instruments, New Castle, DE, US). Nonseeded
CorMatrix was used as control. Seven and 14 days later, the
CM was collected, and the conduits were unstitched and cut
in 3 pieces as for static culture. Further samples were also
taken for mechanical and cell viability studies. The list of
reagents and specific use of derived sCP lines in the
CorMatrix studies are reported in Table S5.
Characterization of Cellularized CorMatrix
Conduits
Histological assessment of the conduit structure: To obtain a
general layout of the cell and interstitial collagen distribution
within the CorMatrix conduit, frozen sections were stained
with hematoxylin and eosin, elastic tissue van Gieson, and
Mallory’s trichrome. Viability and apoptosis: After detachment
from the CorMatrix conduit by enzymatic digestion, cell
viability was determined with trypan blue and apoptosis with
ApopTag Red. In addition, cell viability was assessed in situ
using a Viability/Cytotoxicity immunofluorescent kit (Thermo
Fisher Scientific). Saponin-treated samples were used as
positive controls for cell death. Proliferation: After permeabi-
lization, samples were stained with antiswine Ki67 primary
antibody (Abcam, Cambridge, UK). Expression of mural cell
markers: Sections were incubated with an antiswine neural/
glial antigen 2 (NG2) primary antibody or with antihuman and -
swine a-SMA (a-smooth muscle actin; Sigma-Aldrich, Gilling-
ham, UK), calponin (Abcam), transgelin (Santa Cruz Biotech-
nology, Peaslake, UK), smoothelin (Santa Cruz Biotechnology),
Figure 1. Continued
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and smooth muscle myosin heavy chain (Abcam). Then,
secondary antibodies were added on the sections for 1 hour.
Analysis of collagen secretion: Levels of soluble collagen 1 in
the CM of cellularized conduits were assessed using an
antihuman ELISA kit (R&D Systems, Minneapolis, MN, US).
Mechanical tests of CorMatrix conduits: Elastic modulus,
Figure 2. Functional features of swine cardiac pericytes. (A and B) Clonogenic assay of 2 sCPs lines. A, Images showing the
colony formation after 2 weeks from sorting. Single CPs were deposited to the bottom of a 96 multiwell plate. As indicated in the
tables, 2 fresh cell lines formed an average of 6.9% small colonies and 2 thawed cell lines gave rise to an average of 14.6%
colonies. The second cell line formed new colonies after splitting. B, Immunofluorescent images of colonies from fresh and
thawed cells confirm the positivity for NG2, PDGFRB, and GATA-4 and the negativity for CD31 antigen. C, Bar graphs show
expression of VEGF-A, ANG1, and ANG2 in sCP and sPAEC lysates. Values are meansSEM, N=5 per each group. D, Bar graphs
show VEGF-A, ANG1, ANG2, and bFGF protein levels in the CM of sCP and sPAECs. Values are meansSEM, N=4 per each group.
(E and F) Direct and paracrine angiogenic activity of sCPs in a Matrigel assay. E, Representative phase-contrast images (1009
magnification) of networks formed by sPAECs and sCPs cultured alone or in combination (sCPs to sPAECs at a 2:5 ratio) on
Matrigel substrate for 6 hours. sCPs were stained with the long-term cell tracker, chloromethylbenzamido (Dil; red fluorescence),
to assess the ability to cooperate with sPAECs in forming network structures. Bar graph showing the cumulative tube length per
field. F, Representative phase-contrast images of network formation by sPAECs cultured on Matrigel in the presence of
unconditioned media (UCM) or sCP conditioned media (CM) for 6 hours. Bar graph showing the cumulative tube length per field.
Values are meansSEM, N=4 per each group. ANG1 indicates angiopoietin 1; ANG2, angiopoietin 2; bFGF, basic fibroblast growth
factor; GATA-4, cardiac transcription factor-4; NG2, neural/glial antigen 2; PDGFRb, platelet-derived growth factor receptor beta;
PPIA, peptidylprolyl isomerase A; sCPs, swine cardiac pericytes; sCP-CM, swine cardiac pericyte-conditioned media; sPAECs,
swine pulmonary artery endothelial cells; VEGF-A, vascular endothelial growth factor A.
DOI: 10.1161/JAHA.119.014214 Journal of the American Heart Association 5
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maximum tensile stress, and strain at rupture of unseeded
and cellularized conduits (N=4 biological replicates) were
measured using an Instron 3343 device. A swine left
pulmonary artery (LPA) specimen served as control.
In Vivo Feasibility Study in Piglet Model of LPA
Reconstruction
Two 9-week-old littermate Landrace female piglets, under
general anesthesia and neuromuscular blockade, underwent
LPA resection to accommodate the conduit (~10 mm long and
~6 mm in diameter), as previously reported11 and described in
detail in Data S1. One piglet received a conduit cellularized
with sCPs from a sister piglet and cultured under static
(5 days) and dynamic conditions (7 days). The other piglet
was implanted with an unseeded conduit. Animals recovered
under intense postoperative monitoring for the initial
24 hours. Imaging studies were performed using a 2-
dimensional Doppler echocardiography system (VividQ; GE
Healthcare, Cardiff, UK) and a cardiac magnetic resonance 3-
Tesla scanner (Siemens Healthcare, Erlangen, Germany) at
baseline and 4 months after implantation, with further
echocardiography at 1, 2, and 3 months postsurgery. Then,
swine were euthanized, and the grafted LPA was harvested.
Tissue was snap frozen, fresh frozen in optimal cutting
temperature compound, or fixed in 4% paraformaldehyde
before paraffin inclusion. Sections were used for histology,
immunohistochemistry, and morphometric analyses.
Statistical Analyses
The Student t test was used when comparing 2 groups and
ANOVA with post hoc when comparing >2 groups. Values are
expressed as meansSEM or SD. Probability values (P) <0.05
were considered significant. Results from the in vivo feasibility
study are reported in a descriptive format.
Results
Immunohistochemical Localization of sCPs
Multiple target immunohistochemistry was used for cell-type
localization in cardiac tissue (Figure 1). CD31pos/CD34pos
ECs were typically found around the lumen of capillaries and
arterioles. Moreover, we identified CD31neg/CD34pos/NG2pos
cells around capillaries (Figure 1A) and especially within the
external lamellae of arterioles (Figure 1B).
Antigenic Profile of Expanded sCPs
To isolate and generate stocks of sCPs from piglets hearts, we
used a modified version of the standard operating procedure
previously used on leftovers of CHD reconstructive surgery,3
the main changes being the substitution of fetal bovine serum
with swine heat-inactivated serum (as a constituent of the
growth medium) and swine gelatin (as a coating material of
culture dishes). For the purpose of the present study, we have
successfully isolated and expanded 15 CP lines from pieces of
piglet cardiac ventricles as small as 0.01 g in weight (lowest
limit of success).
We demonstrated that expanded cells have a typical
spindle-shaped morphology (Figure 1C). Cells grew quickly
in culture with an average doubling time of 44.5 (using
fresh cells) and 41.7 hours (using thawed cells). From the
initial seeding number (30 000 cells), sCPs reached the
final counts of ~600 000 (fresh) and ~500 000 cells
Figure 2. Continued
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(thawed) at 8 days of culture (Figure 1D). Viability of
expanded cells was consistently >90% in all the samples
examined (Figure 1E).
Immunocytochemistry analyses illustrated in Figure 1F
and 1G confirmed that expanded cells express the
mesenchymal markers, NG2, PDGFRb (platelet-derived
Figure 3. Chemotactic activity of factors secreted by swine cardiac pericytes. (A through C) In a transwell migration assay,
sCP-CM enhanced the migration of sPAECs. Representative images of migrated cells stained by DAPI (A) or Giemsa (B)
following stimulation with EBM-2 (i), VEGF-A (ii, 100 ng/mL), or CM from 4 sCP lines (iii–vi). Images acquired using a 2009
magnification. (C) Bar graph showing the fold change of migrated cells vs EBM-2 basal media. N=4, data are meanSEM. (D
through F) Effect of Tie-2 inhibitor (7.5 lmol/L) on the chemotactic activity of sCP-CM. Representative images of migrated
cells stained by DAPI (D), or Giemsa (E) following stimulation with EBM-2 (i), CM from 4 sCP lines (ii–v), or CM from the same
sCP lines added with a Tie-2 antagonist (vi–ix) or its vehicle (x–xiii, DMSO). Images acquired using a 2009 magnification. F, Bar
graph showing the fold change of migrated cells vs EBM-2 basal media. Data are meanSEM. Representative
immunofluorescent images of proliferating sPAECs following coculture with sCPs and sCP-CM. (G) sPAECs are stained with
anti-CD31 (red fluorescence) and sCPs with the long-term cell tracker, Dil (yellow fluorescence). Images acquired using 2009
magnification. (H) Bar graph displaying the percentage of EdU+ sPAECS following stimulation with sCPs and sCP-CM. N=4,
data are meanSEM. CD indicates cluster of differentiation; Dil, chloromethylbenzamido; DMSO, dimethyl sulfoxide; EBM-2,
endothelial cell basal medium-2; EdU, 5-ethynyl-20-deoxyuridine; sCP-CM, swine cardiac pericyte–conditioned media; sPAECs,
swine pulmonary artery endothelial cells; Tie2, tyrosine kinase 2; VEGF-A, vascular endothelial growth factor A.
DOI: 10.1161/JAHA.119.014214 Journal of the American Heart Association 7
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growth factor receptor beta), vimentin, and ecto-5-nucleo-
tidase (CD73). Moreover, they were positive for the cardiac
transcriptional binding factor, GATA-binding protein 4, and
the transcription factors, (sex determining region Y)-box 2
and octamer-binding transcription factor 4, but negative for
nanog homeobox (NANOG) and the endothelial markers,
vascular endothelial-cadherin and CD31. When looking at
markers that identify vascular smooth muscle cells,
immunocytochemistry revealed that sCPs express a-SMA
and calponin. Moreover, positive expression for Ki67
confirmed their proliferative activity. Using flow cytometry,
we demonstrated that, like human CPs, sCPs abundantly
express the pericyte marker, PDGFRb, mesenchymal
markers CD105, CD90, CD44, and CD73, while being
negative for CD146, CD31, and the hematopoietic marker,
CD45 (Figure 1H and 1I). sPAECs (Figure 1J) and periph-
eral blood mononuclear cells (Figure 1K) were used as
positive controls for expression of CD31 and CD146
(endothelial markers) and CD45 and CD11b (hematopoietic
markers) in flow cytometry and immunocytochemistry
studies.
Clonogenic Potential of Expanded sCPs
Two biological replicates were sorted as single cells and
cultured in 96-well plates (Figure 2A). Two weeks later, 4.6%
and 9.2% of freshly processed cells formed colonies. The
same cell lines underwent the clonogenic assay after a cycle
of freezing and thawing. In this experiment, colonies were
generated by the 2 cell lines with a frequency of 7.9% and
21.3%, respectively. Of these primary colonies, 2 (0.8%) and 3
(1.3%) from fresh cell lines and 2 (0.8%) and 13 (5.4%) from
thawed cell lines could be further expanded in culture.
Figure 2B shows that clonogenic cells maintained the original
phenotype as assessed by immunocytochemistry.
Angiocrine Properties of Expanded sCPs
qPCR analysis of angiogenic gene trascripts in 5 sCP lines
showed that these cells express more VEGF-A and ANG1 , but
less ANG2, than control sPAECs (Figure 2C). A similar pattern
was observed comparing levels of those angiogenic factors in
the CM (Figure 2D). In addition, FGF-2 protein levels were
remarkably higher in CM of sCPs compared with sPAECs
(Figure 2D). This angiocrine profile resembles the described
paracrine phenotype of human CPs.3 Both sCPs (Figure 2E)
and their CM (Figure 2F) could enhance the network-forming
capacity of sPAECs.
Chemotactic Activity of Expanded sCPs on
sPAECs
Next, we examined whether factors secreted by sCPs may
exert chemoattractant effects on sPAECs, a property instru-
mental to the promotion of in vivo endothelialization of the
graft. Results of a transwell migration assay, where migrated
cells were examined using 40,6-diamidin-2-fenilindolo or
Giemsa staining, revealed that sCP-CM increased the rate of
sPAEC migration by 2-fold compared with endothelial cell
basal medium-2 basal medium or endothelial cell basal
medium-2 supplemented with VEGF-A (Figure 3A through 3C).
Interestingly, the addition of an anti-Tie2 kinase receptor
antagonist inhibited the chemotactic effect of sCP-CM, thus
suggesting that ANG1 signaling is involved in sPAEC attrac-
tion (Figure 3D through 3F).
Proliferation of sPAECs
In addition, we tested whether CPs and their secretome may
stimulate sPAEC proliferation (Figure 3G through 3H). Results
indicate that the abundance of 5-ethynyl-20-deoxyuridine–
Figure 3. Continued
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positive sPAECs was not increased by coculturing them with
sCPs or exposing them to the sCP-CM (72.82.6% and
69.62.3% versus 66.22.3% in sPAECs alone; P=0.29 for
both comparisons). Considering these data in light of the
Matrigel and transwell assays results, we speculate that sCPs
exert proangiogenic effects through stimulation of sPAECs
migration and stabilization of newly formed sPAEC networks,
which would be otherwise subjected to spontaneous regres-
sion in the Matrigel assay.
Incorporation of sCPs in a Clinical-Grade Conduit
Next, we seeded sCPs (20 000 cells/cm2) on CorMatrix, a
clinically approved graft material, and cultured the seeded and
control unseeded conduits for 5 days under static conditions.
In additional experiments, the 2 systems were transferred
from the static condition to a flow bioreactor for a period of 1
or 2 weeks of dynamic culture.
Figure 4 shows representative images from the histology
and immunohistochemistry analyses performed on conduits
harvested at the end of each of the above culture stages.
Staining with hematoxylin and eosin documented that seeded
cells adhered to the surface of the conduit, forming a thicker
layer at 14 days postdynamic culture as compared with
poststatic culture (Figure 4A). In seeded conduits, fibers of
elastin (van Gieson; Figure 4B) and collagen (azan Mallory;
Figure 4C) were clearly detected in proximity of the cell-
seeded area and across the matrix, with the collagen signal
intensity being stronger as compared with unseeded conduits.
A freshly collected swine LPA was used for comparison. The
Figure 4. Histology and immunohistochemistry of CorMatrix grafts seeded with swine cardiac pericytes. (A) H&E staining. (B) Elastin staining
with van Gieson, (C) Collagen staining with Azan Mallory and quantification of grafts and LPA. Immunofluorescence microscopy images of (D)
NG2, (E) a-SMA, and (F) calponin. Microphotographs were collected from samples collected after 5 days of static culture and at 7- and 14-days
culture in the bioreactor. Unseeded control samples are also shown for comparison. BF indicates bright field; CALP, calponin; COL, collagen;
DAPI, 40,6-diamidin-2-fenilindolo; EVG, elastic fibers Van Gieson; H&E, hematoxylin and eosin; LPA, left pulmonary artery; NG2, neural/glial
antigen 2; a-SMA, a-smooth muscle actin.
DOI: 10.1161/JAHA.119.014214 Journal of the American Heart Association 9
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bar graph shows that there was a progressive increase in
collagen content throughout the culture period of the
cellularized graft, which peaked at 14 days of the dynamic
conditioning in the bioreactor (Figure 4C). At this stage, the
initial gap in collagen content between the native CorMatrix
and LPA was almost completely abrogated. As expected,
soluble collagen was undetectable in the CM of control
unseeded CorMatrix. In contrast, secreted soluble collagen
averaged 22.4  4.2 ng/mg of protein in the CM collected
from cellularized CorMatrix (data not shown). These findings
confirm that CPs actively produce ECM proteins (collagen)
and maintain this property once incorporated into the conduit.
Next, we verified whether sCPs maintain their original
phenotype or acquire additional markers after culture of the
conduit under static conditions and subsequent application of
flow in the bioreactor. As expected, control unseeded
conduits did not show any positive staining for the studied
markers, thus confirming these to be acellular. Seeded
conduits collected at the end of the static culture showed
few NG2-expressing cells, with this antigenic cell phenotype
being remarkedly more abundant after application of flow, but
maintaining the original location at the seeded surface of the
conduit (Figure 4D). A similar pattern was observed for the
other natively expressed antigens, a-SMA (Figure 4E) and
calponin (Figure 4F), whereas cells in the conduits were
negative for transgelin, smoothelin, and smooth muscle
myosin heavy chain, thus indicating that they did not acquire
a mature muscular phenotype with transfer from plastic into
the conduit (data not shown).
Viability was assessed in situ with a viability/cytotoxicity
immunofluorescence kit as well as using trypan blue after
cell detachment from the matrix, using trypsin or accutase,
and cell cytospin. Positive controls were treated with
saponin or H2O2. Cells showed a consistently high viability
(>90%) in situ and after detachment with both enzymatic
methods and length of conditioning time (Figure 5A and
5B). Results of terminal deoxynucleotidyl transferase dUTP
nick end labeling assays documented low apoptosis levels
Figure 4. Continued
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Figure 5. Cell viability and proliferation of CorMatrix grafts engineered with swine cardiac pericytes. A, High
viability of sCPs detached from the matrix using 2 enzymatic methods at the end of static and dynamic culture.
B, The data were confirmed using Calcein staining of the grafts. Saponin was used as a control cytotoxic agent.
C and D, Apoptosis was assessed by the TUNEL assay. Bar graph showing results (C) and representative
microscopic images displayed as single and merged channels of 2 different fields in the same sample (i–ii,
blue=DAPI; red=TUNEL; merge=DAPI/TUNEL) (D). Data are meanSEM of 4 biological replicates. E,
Representative images of proliferation assessed by Ki67 staining. Fluorescent images are displayed as single
and merged channels. No staining was detected in unseeded grafts in the different experimental conditions. F,
Graphs showing proliferation following static and dynamic conditions. BF indicates bright field; DAPI, 40,6-
diamidin-2-fenilindolo; PD, postdynamic; PS, poststatic; TUNEL, terminal deoxynucleotidyl transferase dUTP
nick end labeling; +ve control, positive control.
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(<7%; Figure 5C and 5D). Quantitative analysis of cell
proliferation revealed that 8.98.0% of total cells expressed
Ki67 at 5 days of static culture. Frequency of proliferating
cells decreased following dynamic culture (5.41.0% and
2.11.4% Ki67-positive cells at 7 and 14 days, respectively;
Figure 5E and 5F). However, because of large variability of
the measure, the change in proliferation did not reach
statistical significance.
Mechanical Properties of Conduits Engineered
With sCPs
Seeded and unseeded conduits (4 biological replicates,
each one with 3 internal replicates) were tested after 7 and
14 days of maturation in the bioreactor. Representative
curves and cumulative data of the relation between stress
and strain are reported in Figure 6 and Table 1. Analysis of
tensile tests at day 7 displayed a 1.8-fold reduction in
maximum stress for seeded conduits compared with the
unseeded ones (P<0.05), whereas strain at breaking point
and Young’s modulus did not differ between groups. The
conditioning period of 14 days showed a significant
decrease in stiffness, demonstrated by the reduction of
Young’s modulus (1.7-fold versus unseeded; P<0.05) and an
increase in strain at maximum load (1.2-fold versus
unseeded; P<0.05), whereas there was no difference in
maximum stress. Thus, cellularization reduced the mechan-
ical mismatch between native CorMatrix and LPA, support-
ing the feasibility of implantation with a lower risk of
failure.
In Vivo Feasibility Study
Finally, we performed a feasibility study where two 4-week-old
sister weaner piglets underwent LPA surgical replacement
with seeded or unseeded CorMatrix conduits, respectively.
Both animals survived the experimental period and showed
similar growing curves.
• LPA imaging
Figure 7 shows representative images of Doppler and
cardiac magnetic resonance, which confirm the patency of
grafted LPA in both piglets transplanted with seeded or
unseeded grafts. Table 2 reports the individual blood flow
velocity at different times of follow-up, with values within the
normal range for both animals.
• Histological analysis of native PA and implanted grafts
Hematoxylin and eosin images show extensive nucleation
throughout the structure of the proximal and distal seeded
graft (Figure 8A). In both seeded and unseeded grafts, there
were minimal levels of calcification, as assessed using von
Kossa staining (Figure 8B). Elastin is a major component of
the PA. In line with this, van Gieson staining displayed a
consistent layer of organized elastin in the native tissue of the
LPA (Figure 8C). Elastin deposits were visible in the seeded
graft attached to the proximal and distal LPA, but less defined
in the unseeded graft (Figure 8C). Collagen fibers (both
interstitial and perivascular) were detected especially in the
unseeded explant, probably attributable to the formation of a
fibrous scarred tissue. In addition, new muscle tissue
appeared in the LPA and in the perivascular area of the
explants (Figure 8D). The immunohistochemical analysis
showed an organized multilayer of smooth muscle cells
populating the tunica media of the LPA. Endothelial cells
identified by the CD31 marker were present at the luminal
side of the artery and in vessels within the adventitia
(Figure 8E). Cells expressing NG2 were also found in the
Figure 6. Stress-strain curves. A representative line graph show-
ing LPA and CorMatrix mechanical properties in the different
experimental conditions. Circles within the lines indicate maximum
stress values, and triangles indicate the strain at rupture. Average
values of the different biological replicates are reported in Table 1.
LPA indicates left pulmonary artery.











7 days Unseeded 17.72.1 4.20.5 556
Seeded 13.22.6 2.40.3* 564
14 days Unseeded 15.52.1 4.20.6 691
Seeded 8.91.5* 3.10.7 834*,†
LPA 0.550.07 0.280.09 15112
Values are meansSE, N=4 biological replicates, each one with 3 internal replicates. LPA
indicates left pulmonary artery.
*P<0.05 vs unseeded grafts within each time point; †P<0.01 vs corresponding group
(seeded or unseeded) harvested at 7 days of conditioning in the bioreactor.
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adventitia of the vessels. Notably, more organized vessel
structures appeared in seeded graft adventitia compared with
unseeded ones (Figure 8E). Positive staining controls, used in
association with main histological analyses of grafts, are
shown in Figure 8F.
Discussion
Cell therapy and tissue engineering are gaining momentum for
correction of congenital heart defects.12–14 Preclinical studies
have demonstrated the utility of delivering different cell types,
including skeletal myoblasts, cord blood stem cells, and
mesenchymal stromal cells, either intramyo- or epicardially to
treat right ventricle dysfunction and pulmonary artery hyper-
tension induced by pressure or volume overload.15–17 This
experimental evidence was followed by clinical trials, some
already concluded and others still ongoing, in patients with
hypoplastic left heart syndrome reviewed in a previous
work.18 A more-complex endeavor aims to create cellularized
conduits to correct severe cardiac defects, such as tetralogy
of Fallot, which are characterized by a constriction of the right
ventricle outflow tract and PA. Initial evidence indicates that
acellular grafts repopulated with ECs or bone marrow cells are
less susceptible to thrombosis or obstruction.4–6 We recently
developed an alternative approach where a swine small
intestinal submucosa graft functionalized with umbilical
mesenchymal stromal cell-derived vascular smooth muscle
cells was used for replacement of the PA in piglets.11After
6 months from implantation, grafted arteries had developed a
functional intima and media without evidence of aneurism
formation. Using a similar strategy, we have now demon-
strated the feasibility of using CPs to generate living vascular
conduits for reconstruction of the PA. The 2 approaches are
mutually compatible and adaptable to the individual clinical
condition and time of diagnosis. Fetal cell or umbilical cord
stem cells isolated at the time of birth could be used if CHD is
diagnosed prenatally. When diagnosis of CHD is made after
birth or in babies who require a palliative intervention soon
after birth, tissue-specific cardiac cells, such as CPs, could be
isolated from surgical cardiac leftovers to generate living
conduits to be implanted at the occasion of the definitive
correction.3
Human pericytes represent the cell product to be ideally
tested in preclinical safety/efficacy studies before a first-in-
human clinical trial. However, their use in a xenogeneic piglet
model is discouraged because of the adverse effects and
confounding influence of immunosuppression to prevent
rejection. These concerns are particularly serious considering
the need for chronic immunosuppression to be started in
young developing animals. Therefore, the use of a swine
Figure 7. Imaging studies using Doppler echocardiography (A) and cardiac MRI (B). Vascular structures are highlighted (a) aorta, (mpa)
main pulmonary artery, (rpa) right pulmonary artery, and (lpa) left pulmonary artery. Preop indicates preoperation.
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equivalent product is a sensible way forward. Regulatory
agencies are usually reluctant to allowing an animal-equivalent
product where possible, but, under these circumstances, the
Medicines & Healthcare products Regulatory Agency has
provided us with a favorable feedback for swine cells to be
used in piglets for the model rather than human cells in swine.
In addition, the Medicines & Healthcare products Regulatory
Agency’s opinion is that the PA reconstruction used here is an
appropriate in vivo model to assess feasibility and efficacy of
the cell-engineered CorMatrix conduit.
The surrogate cell product was validated through extensive
characterization of antigenic markers, using in situ immuno-
histochemistry, immunocytochemistry, and flow cytometry.
We also confirmed the clonogenic capacity of freshly
processed or thawed single-sorted sPCs. The possibility of
generating frozen stock of CPs provides therapeutic flexibility
for meeting the surgical schedule (ie, surgery happening at a
later time than the one required for the preparation of the
graft) or multistage surgical corrections. In addition, swine
and human pericytes share the ability to recruit ECs and
promote endothelial network formation through secretion of
paracrine factors.3 Pericytes signal to ECs through the binding
of ANG1 to Tie2, resulting in activation of pathways mediating
survival, proliferation, migration, and anti-inflammatory sig-
nals. Using a Tie2 antagonist, here we demonstrated that this
signaling is instrumental to the recruitment of ECs by the sCP
secretome. Our data indicate that sCPs promote the organi-
zation of sPAECs on Matrigel, likely through activation of
migration and inhibition of degradation. This is in line with the
well-known role of pericytes acting as vascular stabilizers of
nascent vascularization.
The use of ECM as a biological scaffold for tissue repair
and regeneration is an established procedure within the
clinical community. Commercial scaffolds manufactured from
a range of ECM materials from different animals are available
for use in cardiac surgery. CorMatrix, the most used product
of this type, is a decellularized porcine small intestinal
submucosa product that has received approval by both the US
Food and Drug Administration and European authorities for
cardiovascular applications. A recent meta-analysis assessing
the results of clinical studies using CorMatrix in pediatric
populations indicates favorable outcomes.19 However, some
of the claimed advantages of the material, such as the
bioinductive capacity to support the ingrowth of reparative
cells from the host without inducing inflammatory reactions,
have been questioned by several reports. Histological exam-
ination of failing grafts showed moderate-to-severe grade
inflammation in the explant tissue without signs of regener-
ation or integration.20–22 Interestingly, these reactions were
not observed in swine models, thus suggesting the possibility
that inflammation was a reaction to antigenic epitopes
present in the swine intestine, but not in humans.22 Moreover,
90% of the CorMatrix is made of collagen type I, but contains
little amounts of elastin,23 which is instead a major compo-
nent of a pulmonary artery and a determinant in maintaining
vascular hemodynamic efficiency.24
Recellularization with stromal cells before in vivo implan-
tation could overcome the inadequate constructive remod-
eling capacity and lack of elasticity of the native cross-
linked CorMatrix. Confirming the data of our previous study
on human pericytes,3 the present report shows that sCPs
proliferate and engraft onto the external surface of
CorMatrix, maintaining a high degree of viability and the
original antigenic phenotype. This is in keeping with the
goal to create a cellularized adventitial layer, from which,
upon in vivo implantation, sCPs could exert paracrine
recruiting effects on the recipient’s cells and timely
remodeling of the matrix. The lack of sCP penetration into
the matrix core before in vivo implantation is, in our
opinion, a positive outcome. In fact, for sPCs to infiltrate
the internal layer of the conduit, the matrix should undergo
degradation. This might result in making the conduit unable
to withstand the mechanical forces in vivo. The equilibrium
between breakdown of the structure attributed to proteases
and production of ECM proteins plays a fundamental role in
the stabilization and rearrangement of the graft as well as
native blood vessel.25 Our results indicate that collagen
content progressively increased in sCP-seeded grafts
throughout the maturation in the bioreactor. Collagen
possesses useful mechanical properties that can confer
the CorMatrix with increased elasticity and greater exten-
sibility before fracture. In line with the above, mechanical
tests at different times of the in vitro maturation process
demonstrated that CorMatrix conduits acquired a more
elastic behavior when seeded with sCPs, as denoted by a
significant decrease in Young’s modulus, but also an
increased strain at rupture. Similar mechanical effects were











Values are mL/sec. LPA indicates left pulmonary artery; MPA, main pulmonary artery;
Postop, postoperation; Preop, preoperation; RPA, right pulmonary artery.
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Figure 8. Analyses of the explanted grafts. A, H&E staining of unseeded and seeded grafts. B, Von Kossa
staining. C, Von Gieson staining. D, Collagen staining. E, Immunohistochemistry of LPA and explanted grafts. Cells
expressing a-SMA (red) and CD31 (white) are present in the internal layer and luminal site of the native tissue and
graft. In addition, NG2-positive cells (green) were identified in the adventitia around the vasa vasorum. F, Positive
control tissues for immunohistochemistry graft comparison. Swine saphenous vein showing H&E (i) and EVG
staining (ii, cells and elastic fibers, respectively). Swine MI heart biopsy displaying Azan Mallory staining (collagen)
in the remote area (iii). Aortic valve from swine MI model showing Von Kossa staining for identification of
microcalcifications (iv). Swine health cardiac tissue stained with Ki67 for cell proliferation (v). ADV and PA indicate
adventitia and pulmonary artery (yellow color); CD, cluster of differentiation; COL, collagen; DAPI, 40,6-diamidin-2-
fenilindolo; EVG, elastic fibers Van Giesons’; H+E, hematoxylin and eosin; LPA, left pulmonary artery; MI,
myocardial infarction; NG2, neural/glial antigen 2; SMA, smooth muscle actin.
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reported by Sodian et al in a study using tissue-engineered
trileaflet heart valves.26
The in vivo study provided us with valuable data in
preparation of a properly designed efficacy trial, but also
highlighted the strengths and weaknesses of the swine model.
We used Doppler and cardiac magnetic resonance imaging to
measure blood flow velocity and confirm the patency of the
implanted graft. The values of blood flow velocity from the
present study are consistent with a previous report.11 A
power calculation based on combined data from the 2 studies
indicate that a minimum of 7 animals per group would be
necessary to detect a difference of 0.3 mL/min with an SD of
0.2. Our previous study confirmed that graft stenosis is a rare
event in swine compared with humans,11 possibly attributa-
ble, as mentioned above, to a lower inflammatory reaction to
a product from the same species. Therefore, hemodynamic
outcomes should be considered in combination with histo-
logical outcomes, such as matrix remodeling, endothelializa-
tion of the intima, and cellularization of the media and
adventitia, as shown in the present report.
Conclusions
We demonstrated that sCPs can be used as a cell
surrogate of human CPs to engineer CorMatrix conduits
implantable in the piglet’s LPA. A controlled randomized
efficacy/safety study based on this technology is currently
ongoing with provision to be completed by March 2020.
The completion of the full study would provide clear
evidence of the advantage of using pericytes-engineered
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structural and functional performance. This novel approach,
using cells extracted from small pieces of cardiac tissue
available during palliative surgery, may open new avenues
for correction of congenital cardiac defects with remarkable
medical and social benefits.
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Harvesting and processing of cardiac tissue  
Four-weeks-old Large white/Landrace piglets (UK registered breeder) were euthanized with 
Euthatal, and heart samples were harvested for in situ identification and isolation/expansion of 
swine cardiac pericytes (sCPs) (Table S1). Peripheral blood was collected via an indwelling 
jugular vein cannula for isolation of peripheral blood mononuclear cells (PBMNCs) and extraction 
of serum to be used for sCP expansion. In some experiments, commercial swine heat-inactivated 
serum (Sigma-Aldrich, UK) was used in alternative to the piglet serum. 
 
In situ immunohistochemistry of sCPs 
Cardiac tissue samples were collected and fixed in 4% (w/v) PFA (Sigma-Aldrich, UK) for 16 
hours, at +4°C. After one wash in 1x Phosphate Buffered saline (PBS), fixed samples were placed 
in 30% (w/v) Sucrose for 48 hours, at +4°C, and embedded in OCT (O.C.T. Compound, VWR, 
UK, cat n: 361603E). Eight-micron sections were cut and fixed in ice-cold glacial Acetone (Fisher, 
UK) for 5 min, at -20°C. After fixation, sections were kept air-dried for 20 min and hydrated in 
1x PBS. 0.01% (v/v). Triton X-100 (Sigma-Aldrich, UK) was used for the membrane 
permeabilization for 10 min, at RT. Non-specific binding sites were blocked using 5% (v/v), foetal 
bovine serum (FBS, Life Technologies, UK) in 1x PBS as blocking solution. Double staining 
combinations of anti-swine NG2/anti-human CD31 and anti-swine CD34/anti-human CD31 
primary antibodies were used. After a 16-hour incubation at +4°C, sections were washed in 
1xPBS, and secondary antibodies were incubated on the sections for 1 hour, at RT, in the dark 
(Table S2). The nuclei were counterstained with DAPI (Sigma-Aldrich). The slides were mounted 
using Fluoromount-G® mounting media (Sigma-Aldrich) and immunofluorescent images were 
taken using x10, x20 objectives of Zeiss Observer.Z1 microsope (Carl Zeiss Microscopy, LLC, 
US) and Zen pro software.  
 
CP isolation and expansion 
Cardiac samples were processed using a modification of the GMP-compliant standard operating 
procedure (SOP) previously employed for isolation/expansion and characterization of CPs from 
the neonatal human heart.3 Briefly, single cell suspensions of immunomagnetically-sorted CD31-
CD34+ cells were cultured onto dishes coated with 1% (w/v) swine gelatin (Sigma-Aldrich) 
containing Endothelial Cell Growth medium-2 (EGM-2, Promocell, UK) supplemented with 10% 
(v/v) heat-inactivated swine serum (Sigma-Aldrich), and 1% (v/v) Penicillin and Streptomycin 
(Pen/Strep). Once reached 80-90% confluence, primary colonies were passaged to new culture 
dishes. At P2, cells were split for further expansion or generation of frozen stocks.  
 
Assessment of sCP characteristics 
• Immunocytochemistry 
Expanded cells (N=7 biological replicates run in triplicate) were fixed with freshly prepared 4% 
(w/v) PFA in 1x PBS for 10 min at +4°C , washed with 1x PBS and probed with the indicated 
antibodies (Table S2). For detection of intracellular antigens, cells were permeabilized for 10 min 
at +4°C with 0.1% (v/v) Triton X-100 (Sigma-Aldrich) diluted in 1x PBS. Cells were incubated 
with the indicated primary antibodies (16 hours at +4°C) and appropriate secondary antibodies 
(1:200 anti-rabbit Alexa 488 or 1:200 anti-mouse Alexa 488, 1 hour at +20°C in the dark). The 
nuclei were counterstained with DAPI (Sigma-Aldrich). Slides were mounted using Fluoromount-
G (Sigma-Aldrich). Cells were analyzed at a 200X and 400X magnification. Zeiss Observer.Z1 
and Zen pro software were utilized to compose and overlay the images. Swine Pulmonary Artery 










• Flow cytometry 
Cells (1x106, N=3 biological replicates) were washed in 1X DPBS (Life Technologies) and treated 
with 1x trypsin/EDTA (Life Technologies). Then, they were washed, spun at 400xg for 10 min at 
+4°C and re-suspended in FACS-staining buffer containing 0.1% (w/v) BSA, 1mM EDTA and 
0.1% (v/v) sodium azide, followed by blocking of unspecific binding with 10% (w/v) BSA in 1X 
DPBS. Next, 2x105 cells/tube were incubated with antibodies for 30 min at +4°C, in the dark 
(Table S3). For detection of the endothelial marker CD31, cells were washed twice in FACS 
buffer. The flow cytometry procedure included Fluorescence Minus One (FMO) controls. sPAECs 
were used to verify the expression of endothelial antigens. In addition, we used the Fixable 
Viability Dye eFluor 780 (eBioscience, UK) to label dead cells and exclude them from the gating 
strategy. Prior to sample acquisition, the cells were fixed with 1% (v/v) PFA in 1x PBS. 
• Clonogenic assay:  
The test was performed on two sCP lines at P3, using a motorized device connected to the flow 
cytometric sorter (Cyclone, Beckman Coulter, US). Sorted cells were placed into each well of a 
96‐well culture plate (Greiner Bio‐one, UK) and cultured up to 4 weeks in EGM‐2 for 
quantification of colonies generated from a single cell. A comparative assay between fresh and 
frozen-thawed sCPs was performed to assess if both conditions allow the generation of clones. 
• Quantitative PCR of angiogenic factors 
Total RNA was obtained from cultured sCPs (miRNeasy mini kit, Cat n: 217004, Qiagen) and 
reverse‐transcribed using a High Capacity RNA‐to‐cDNA Kit (Cat n: 4387406, Life 
Technologies). The reverse transcription–PCR was performed using the first‐strand cDNA with 
TaqMan Fast Universal PCR Master Mix (Cat n:  4324018, Life Technologies) and on a Quant 
Studio 6 Flex Real-Time PCR system (Applied Biosystems) for the genes specified in Table S4. 
• Secretion of angiogenic factors  
Dedicated anti-human ELISA kits were used to measure the immunoreactive levels of Vascular 
Endothelial Growth Factor-A (VEGF-A), Angiopoietin 1 (ANG 1), Angiopoietin 2 (ANG 2), and 
basic Fibroblast Growth Factor (bFGF) proteins in conditioned media (CM) from sCPs, which 
were cultured for 48 hours in 2.5 mL serum-free, endothelial basal medium 2 (EBM-2) under 
normoxia. All the ELISA kits were from R&D System (cat n: DY293B, DY923, DY623, DY233-
05, respectively). SPAECs were used as a control. The optical density (OD) of each well was 
determined using a Dynex Opsys MR microplate reader (Aspect Scientific, UK) set to 450 nm. 
• Endothelial network formation 
The capacity of cells to form networks on Matrigel was assessed using sCPs or sPAECs alone or 
both in coculture. In addition, the network formation capacity of sPAECs was assessed following 
stimulation with sCP-CM or unconditioned media (UCM). First, sCPs were labelled with the long-
term cell tracker Dil (Thermo fisher cat n: C7001). Cells were seeded on top of 70 μL thick-coated 
Matrigel (BD Biosciences) in EGM2 for 6 hours. Images were taken under bright field at 5× and 
the length of the networks was measured. 
• Chemotactic activity  
Here, we tested the capacity of the sCP-CM to induce the migration of sPAECs. The latter were 
seeded on transwell cell culture inserts equipped with 8 µm pore size polycarbonate membranes 
(Corning, cat n: 3422) in EBM-2 basal medium. The migration of sPAECs was stimulated by 
adding 500 µL of sCP-CM to the bottom of the same wells. In parallel, EBM-2 basal medium or 
EBM-2 supplemented with 100 ng/mL of swine recombinant VEGF-A (Cambridge Bioscience, 
cat n: RP0403S-005) were used to assess spontaneous and growth factor directed migration.  In 
separate assays, an antagonist of Tie-2 kinase receptor (Abcam, cat n: 141270) was used to contrast 
the effect of the sCP-CM on migration. After 16-hour incubation at +37°C, the polycarbonate 
membranes were washed and scraped with a cotton swab to remove non-migrating cells. Migrated 








the membranes were fixed in 4% (w/v) PFA and 100% (v/v) Methanol. GIEMSA stain solution 
was added for 60 min at RT, protected from light. For staining of nuclei, the membranes were 
washed in 4% (w/v) PFA and incubated with 1:1000 DAPI for 2 min at RT. In either case, 
membranes were washed twice and gently removed from the inserts with a scalpel for the 
visualization of the cells and nuclei, respectively. Membranes were analyzed with an 
epifluorescence microscope at ×200 magnification; 10 fields were randomly acquired, and cells 
counted. Migrated cells were expressed as a percentage of total seeded cells.  
• Endothelial cell proliferation 
The capacity of sPAECs to proliferate in the presence of sCPs and sCP-CM was assessed by Click-
iT™ EdU (5-ethynyl-2'-deoxyuridine) Cell Proliferation Kit for Imaging, Alexa Fluor™ 488 dye 
(Thermo fisher, cat n: C10337) using UCM and sCP-CM media. Briefly, sCPs were labelled with 
Dil according the manufacturer’s instructions prior to seeding for the assay. Swine PAECs and 
sCPs were seeded into plastic dishes and the EdU was incubated for a minimum of 16 hours with 
EBM-2 and sCP-CM. Cells were fixed in 4% (w/v) PFA and the membrane were permeabilized 
using 0.1% (v/v) Triton X-100. The EdU detection reagents were added to the wells for 30 minutes 
and an anti-swine CD31 primary antibody (Abcam cat n: ab28364) was incubated overnight, at 
+4 °C, protected from light. A secondary antibody was used to detect sPAECs stained with CD31 
antigen. Cells were incubated with 1:10,000 HOECHST for 3 minutes, at +21 °C, protected from 
light. Fluorescent images were taken with a fluorescent microscope and 10 fields were acquired 
randomly using 20X magnification objective. Proliferative sPAECs were counted as a percentage 
of total sPAECs seeded. 
 
Studies on cellularized CorMatrix  
• Static culture of sCPs on CorMatrix 
Pieces of CorMatrix® ECM® (CorMatrix Cardiovascular, Sunnyvale, CA) were cut, firmly 
positioned at the bottom of wells of a 48-well plate using Cell Crown inserts (Sigma-Aldrich), and 
primed with EGM-2 media for 48 hours. Next, sCPs (P5, 20,000/cm2) were seeded into each 
CorMatrix-containing well and cultured for 5 days. The CM was then collected and the CorMatrix 
samples were cut in three pieces: one was fixed in 4% (w/v) PFA for 16 hours at +4°C and 
embedded in paraffin for histological studies, while the other two pieces were OCT-frozen for 
molecular biology analyses. Eight biological replicates were examined unless differently 
specified.  
• Dynamic culture of sCPs on CorMatrix 
After completion of the 5-day static culture, sCP-seeded CorMatrix was further grown in a 3D 
CulturePro™ Bioreactor (TA instruments, USA). Non-seeded CorMatrix was used as control. The 
conduit was stitched to the rotating arm of the Bioreactor and stitched back onto itself to fashion 
a tube shape through the centre of which runs the rotating arm. The bioreactor was filled with 
EGM-2 media supplemented with 10% (v/v) swine serum and 1% (v/v) Pen/Strep and maintained 
in the incubator at +37°C. Seven and fourteen days later, the CM were collected, and the conduits 
were unstitched and cut in three pieces: one was fixed in 4% (w/v) PFA for 16 hours at +4°C and 
embedded in paraffin, and the two other pieces were frozen for OCT-embedding and for RNA and 
protein analysis. Four biological replicates were examined unless otherwise specified. The list of 
swine and specific experimental usage of derived sCP lines in the CorMatrix studies is reported in 
Table S5.  
• Characterization of cellularized CorMatrix grafts  
Histological assessment of the graft structure: To obtain a general layout of the cells, elastin, and 
interstitial collagen distribution within the CorMatrix grafts, frozen sections were stained with 
Haematoxylin and Eosin (H&E), Elastic tissue-Van Gieson’s (EVG), and Mallory’s trichrome 
using a Shandon Varistain 24-4 slide stainer (Thermofisher, UK) on slides mounted with DPX 








Observer.Z1 with Zen Blue software. Collagen deposits onto grafts were quantified as percentage 
of total area using ImageJ software. 
Viability and apoptosis: Cells were detached from the CorMatrix graft by enzymatic digestion and 
cytospun for 5 min at 500 rpm at RT onto histology slides using an EZ double cytofunnelTM 
(Thermofisher, UK cat n: A78710005) and a cytospin machine (Cytospin 4, Thermofisher, UK). 
Two different enzymes (Trypsin and Accutase) were used for cell detachment. Viability was 
determined with Trypan blue and apoptosis with Apoptag Red In situ Apoptosis Detection Kit 
(Millipore, UK cat n: S7165). As a positive control for apoptosis, sCPs were treated with 15 µm 
H2O2 (Sigma, UK cat n: H1009) for 1 hour at +37°C. In addition, cell viability was assessed in 
situ (without detaching cells from the graft) at 5 days post-static and 7 days post-dynamic culture 
using a Viability/Cytotoxicity immunofluorescent kit (Thermofisher, UK, cat n: L3224). Saponin 
(Sigma-Aldrich) treated samples were used as positive controls. Grafts were imaged using Zeiss 
microscope.  
Proliferation: After permeabilization with 0.1% (v/v) Triton X-100, samples were stained with 
anti-swine Ki67 primary antibody (Abcam, UK, cat n#: ab15580).  
Expression of mural cell markers: Here, we determined the effect of engraftment on the expression 
of pericyte and Vascular Smooth Muscle Cell (VSMC) markers. Eight-micron sections from 
frozen samples were cut and fixed in ice-cold glacial Acetone (Thermofisher) for 5 min at -20°C. 
After fixation, sections were kept air-dried for 20 min and hydrated in 1x PBS. Non-specific 
binding sites were blocked using 5% (v/v) foetal bovine serum (FBS Life Technologies, UK) or 
10% (v/v) Normal Goat serum (NGS, Life Technologies) in 1x PBS as blocking solution. Sections 
were incubated for 16 hours, at +4°C, with an anti-swine NG2 primary antibody or with anti-
human and anti-swine α-Smooth Muscle Actin (α-SMA, Sigma, UK), Calponin (CALP, Abcam, 
UK), Transgelin (TAGLN, Santa-Cruz, UK), Smoothelin (SMTN, Santa Cruz, UK), and Smooth 
Muscle Myosin Heavy Chain (SMMHC, Abcam, UK). Secondary antibodies were incubated on 
the sections for 1 hour, at RT, protected from the light. The nuclei were counterstained with DAPI. 
The slides were mounted using Fluoromount-G® mounting media (Sigma-Aldrich) and 
immunofluorescent and brightfield images were taken using x2.5, x10, x20 objectives of Zeiss 
microscope.  
Analysis of collagen secretion by CorMatrix grafts: The CM of cellularized grafts (collected after 
culture under static or dynamic conditions) were centrifuged at 400 g for 10 min at RT to assess 
the levels of soluble Collagen 1 (COLIA1) using an anti-human COLIA1 ELISA kit (R&D 
Systems, cat n: DY6220-05). The OD value was measured using a microplate reader set to 450 
nm.  
Mechanical tests of CorMatrix grafts: The elastic modulus, maximum tensile stress and strain at 
rupture were measured using an Instron 3343 device (Illinois Tool Works Inc., USA). The study 
was conducted on unseeded and cellularized grafts (N=3 biological replicates) and a swine Left 
Pulmonary Artery (LPA) specimen serving as control. In detail, CorMatrix tubular structures, 
seeded and unseeded, were opened along the stitches and cut to obtain a rectangular-shaped sample 
with length of 20±5mm, width of 6.5±0.35mm and thickness of 3.5±0.15mm. Tests were 
performed at +37⁰C in PBS, the distance between the two clamps was set to 10±1mm and 
specimens were subjected to strain rate of 0.01 min−1 until failure. Stress–strain curves of grafts 
and swine LPA (control) were derived from the load-elongation data.  
 
In vivo study assessing the feasibility of implanting a cellularized graft conduit in piglet LPA 
Surgical procedures were performed with swine under general anesthesia 
(Ketamine/Midazolam/Dexmedetomidine, Isoflurane) and neuromuscular blockade 
(Pancuronium Bromide). Details of the operation have been reported previously.11 Briefly, a left 
posterolateral thoracotomy was performed in two 4-week-old sister Landrace female piglets. The 








was clamped and a 3–4 mm of the LPA was resected to accommodate the conduit-shaped graft 
(~10 mm long and ~6 mm diameter). One piglet received a conduit cellularized with sCPs from a 
sister piglet and cultured under static (5 days) and dynamic condition (7 days). The other piglet 
was implanted with an unseeded conduit. Animals recovered under intense postoperative 
monitoring for the initial 24 hours. Analgesic (Paracetamol, Morphine) and antibiotics 
(Cefuroxime) were administered during this period according to the needs. 
Imaging studies were performed using a two-dimensional Doppler Echocardiography 
system (VividQ, GE Healthcare, UK) and a cardiac magnetic resonance 3-T scanner (Siemens 
Healthcare, Erlangen, Germany) at baseline and 4 months after implantation. Then, swine were 
euthanized by an overdose of IV pentobarbitone according to the surgical facility standard 
protocols. The grafted LPA was harvested and stored in PBS on ice until transported to the 
laboratory. Tissues were either snap frozen in OCT or fixed in 4% (w/v) PFA before OCT or 
paraffin inclusion and histology analysis. 
 
Immunohistochemistry of vascular graft conduits 
For a general overview of the grafted LPA structure, we performed H&E and elastin staining. 
Azan Mallory staining was used for the detection of fibrosis in the explants. The occurrence of 
microcalcifications was assessed using Von Kossa (Millipore, UK, cat n: 1.00362.0001). 
Endothelial cells in the intima and mural cells in the tunica media were recognized using 
antibodies reported in Table S2. Images were captured using a Zeiss Axio Observer.Z1 equipped 
with a Zen Blue software. 
 
Statistical analyses 
Average values are plotted with group size value shown in figure legends. Statistical significance 
for differences between experimental groups was determined using Student's t-test when 
comparing two groups and ANOVA with post-hoc when comparing more than two groups. Values 
were expressed as means±standard error of the mean (SEM) or standard deviation (SD). 
Probability values (P) <0.05 were considered significant. Results from the in vivo feasibility study 










Table S1. Code of donor neonatal swine and analyses performed on corresponding cardiac samples and isolated cells. 
 
Swine code Weight (g) Experimental use 
240617A 0.9 Immunohisto-cytochemistry, PCR, ELISA, Migration assay w/o anti-Tie2 
080717A 0.08 Immunohisto-cytochemistry, PCR, Matrigel-co, Migration assay w/o anti-Tie2 
080717B 0.08 Immunocytochemistry, FACS, PCR, Matrigel-co/CM, ELISA, Migration assay without anti 
Tie2, EdU assay 
060917A 0.09 Immunocytochemistry, Growth curve- Viability-DT, FACS, Clonogenic assay, PCR, Matrigel-
co, ELISA 
060917B 0.09 Growth curve- Viability-DT, FACS, Matrigel-co/CM, ELISA, Migration assay without anti-
Tie2, EdU assay 
060917C 0.09 Immunocytochemistry, Growth curve -Viability-DT, Clonogenic assay 
140618A 0.2 PCR, Matrigel-CM, Migration assay-anti-Tie2, EdU assay  
190618A 0.013 Immunocytochemistry, Matrigel-CM, Migration assay-anti-Tie2, EdU assay 























Table S2. Antibodies used in immunohistochemistry and immunocytochemistry studies. 
 
Marker Technique Permeabilization Reactivity Primary antibody 





Yes Human/Swine Sigma, 1:400 Cy3-conjugated 
Calponin ICC-IF, 
IHC-IF 
Yes Human/swine Abcam, 1:100 Invitrogen, A488 Goat α-Rabbit 
CD31 ICC-IF Yes Swine Abcam, 1:20 Invitrogen, A488 Goat α-Rabbit 
CD31 IHC-IF No Human R&D, 1:50 Invitrogen A647 highly adsorbed Goat 
α-mouse 
CD34 IHC-IF Yes Swine Abcam, 1:100 Invitrogen A488 Goat α-Rabbit 
CD73 ICC-IF Yes Swine R&D, 1:10 Invitrogen, APC donkey anti-sheep 
CD146 ICC-IF Yes Human/Swine Abcam, 1:100 Invitrogen, A488 Goat α-Rabbit 
GATA-4 ICC-IF Yes Human Abcam, 1:100 Invitrogen, A488 Goat α-rabbit 
NANOG ICC-IF Yes Human Abcam, 1:100 Invitrogen, A488 Goat α-mouse 
NG2 ICC-IF, 
IHC-IF 
Yes Swine NovusBiological, 1:50 Invitrogen, A488 Goat α-Rabbit 
OCT-4 ICC-IF Yes Human/Swine Abcam, 1:100 Invitrogen, A488 Goat α-Rabbit 
PDGFRβ ICC-IF Yes Swine GeneTex, 1:100 Invitrogen, A488 Goat α-Mouse 
SMMHC11 ICC-IF, 
IHC-IF 
Yes Human/swine Abcam, 1:100 Invitrogen, A488 Goat α-Rabbit 
Smoothelin ICC-IF, 
IHC-IF 
Yes Human/swine Santa-Cruz, 1:100 Invitrogen, A488 Goat α-Mouse 
SOX2 ICC-IF Yes Human/Swine Merck Millipore, 1:100 Invitrogen, A488 Goat α-Rabbit 
Transgelin ICC-IF, 
IHC-IF 
Yes Human Santa-Cruz, 1:50 Invitrogen, A488 Goat α-Mouse 
VE-cadherin ICC-IF Yes Human/Swine Santa Cruz, 1:50 Invitrogen, A488 Goat α-Mouse 










Table S3. Antibodies used in flow cytometry studies. 
 
Marker Permeabilization Reactivity Primary antibody 
source dilution 
Fluorophores 
CD31 No Swine Serotec, 1:80 PE 
CD44 No Swine eBioscience, 1:20 APC 
CD45 No Swine Serotec, 1:25 FITC 
CD73 No Swine R&D, 1:10 Invitrogen, APC donkey anti-
sheep 
CD90 No Swine eBioscience, 1:20 Pe-Cy7 
CD105 No Swine LifeSpan, 1:5 PE 
CD146 No Swine Serotec, 1:60 FITC 
PDGFR No Human Biolegend, 1:25 PE 









Table S4. TaqMan probes used in the molecular biology studies.  
 
Gene Species Assay ID 
ANG1 Swine Ss03391075_m1 
ANG2 Swine Ss03392362_m1 
PPIA (housekeeper) Swine Ss03394782_g1 











Table S5. Analyses performed on sCP-engineered grafts. 
 
Swine code Post-static  Post-dynamic In vivo  
240617A H&E, EVG, Collagen, Proliferation, Apoptosis, 
NG2 and VSMC markers  
H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, 
VSMC markers, and Mechanical tests 
 
080717A Collagen   
080717B Viability, H&E, EVG, Collagen, Proliferation, 
Apoptosis, NG2 and VSMC markers 
Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, 
NG2 and VSMC markers 
 
060917A H&E, EVG, Collagen, Proliferation, Apoptosis, 
NG2 and VSMC markers 
H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, 
VSMC markers, and Mechanical tests 
 
060917B H&E, EVG, Collagen, Proliferation, Apoptosis, 
NG2 and VSMC markers 
H&E, EVG, Collagen, Proliferation, Apoptosis, NG2, 
VSMC markers, and Mechanical tests 
 
191217A Viability   
140618A Viability, H&E, EVG, Collagen, Proliferation, 
Apoptosis, NG2 and VSMC markers 
Viability Engraftment 
190618A Viability, H&E, EVG, Collagen, Proliferation, 
Apoptosis, NG2 and VSMC markers 
Viability Engraftment 
240718A Viability, H&E, EVG, Collagen, Proliferation, 
Apoptosis, NG2 and VSMC markers 
Viability Engraftment 
050918A H&E, EVG, Collagen, Proliferation, Apoptosis, 
NG2 and VSMC markers 
 Engraftment 
050918B H&E, EVG, Collagen, Proliferation, Apoptosis, 
NG2 and VSMC markers 
 Engraftment 
30.01.19A   Engraftment 
30.01.19 B Viability Viability Engraftment 
Unseeded Graft Viability, H&E, EVG, Collagen, Proliferation, 
Apoptosis, NG2 and VSMC markers 
Viability, H&E, EVG, Collagen, Proliferation, Apoptosis, 
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